Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: PDS And Edge Merge To Progress HPV-Linked Cancer Immunotherapy

Executive Summary

Immunotherapy firms Edge and PDS announce planned merger, while Telix advances its prostate cancer strategy by acquiring ANMI. Kyowa Hakko Kirin is signed up to distribute GlaxoSmithKline's Phase III CKD-associated anemia product daprodustat in Japan.

You may also be interested in...



Asia Deal Watch: Athenex Changes Mind, Gets Back Chinese Rights To Actinic Keratosis Candidate

Following a positive Phase III data readout for KX2-391, Athenex requests dissolution of its recent deal conferring rights to the drug in China to Chongqing Jingdong Junzhuo. TaiwanJ licenses Asian rights outside its home market for JK-122 to Newsoara.

Multinationals Eye Divesting Established Products In China Amid Fierce Competition, Shifting Focus

Farewell established products, hello innovative new drugs! As pricing pressures mount, more multinational companies including Lilly and Roche are switching their business focus in China, looking at product divestments and partnering with local firms.

Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset

Roivant Sciences has added iNtRON Biotechnology’s novel biologic candidate to its existing anti-infective portfolio in a sizable licensing deal amid recent increased global health attention on antimicrobial resistance issues but generally decreasing pharma industry interest.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC124231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel